Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
PLIANT THERAPEUTICS, INC. | Director | Common Stock (Right to Buy) | 26.8K | $55.7K | $2.08 | Jun 13, 2024 | Direct |
Pyxis Oncology, Inc. | Director | Stock Option (Right to Buy) | 37K | $36.2K | $0.98 | Mar 31, 2025 | Direct |
IMPEL PHARMACEUTICALS INC | Director | Stock Option (right to buy) | 13.2K | Jun 16, 2023 | Direct | ||
GW PHARMACEUTICALS PLC | U.S. Chief Commercial Officer | Ordinary Shares | 0 | May 5, 2021 | Direct | ||
GW PHARMACEUTICALS PLC | U.S. Chief Commercial Officer | Share Options | 0 | May 5, 2021 | Direct | ||
IMPEL PHARMACEUTICALS INC | Director | No securities beneficially held. | 0 | Apr 12, 2023 | Direct |